Dysregulation of m6A deposition is associated with various diseases including cancer pathogenesis and drug resistance (Huang et al., 2020; Lan et al., 2021; Zhang et al., 2021), such as the core m6A methyltransferase (METTL3) promotes the progression of breast cancer through elevating expression of mammalian hepatitis BX-interacting protein and inhibiting tumor suppressor let-7g (Cai et al., 2018), inhibits tumor immune surveillance by upregulating PD-L1 mRNA level (Wan et al., 2022), and contributes to breast cancer tamoxifen resistance by upregulation of AK4 expression (Liu et al., 2020). This evidence concerns the gene CD274 and breast carcinoma.